Reeves Donald L. III 4
4 · ITRON, INC. · Filed Feb 20, 2026
Research Summary
AI-generated summary of this filing
Itron (ITRI) SVP Donald L. Reeves III Receives 20,017-Share Award
What Happened
- Donald L. Reeves III, Senior Vice President, Outcomes at Itron (ITRI), received two awards on 2026-02-18 totaling 20,017 shares (6,527 and 13,490 shares). Both were granted at $0.00 (awarded, not purchased), according to the Form 4 filed 2026-02-20.
- These are equity awards (code A) — one award is a performance-based restricted stock unit (RSU) for the 2023–2025 performance period.
Key Details
- Transaction date: 2026-02-18; Form 4 filed: 2026-02-20 (appears timely).
- Shares awarded: 6,527 and 13,490 = 20,017 total; acquisition price: $0.00 (awards).
- Vesting/conditions: Footnote F1 — one-third vests on the first anniversary of the grant, remaining two-thirds vest in equal quarterly installments over the following 24 months. Footnote F2 — the 13,490 shares represent performance-based RSUs earned for 2023–2025.
- Shares owned after the transaction: not specified in the provided filing excerpt.
- Transaction type: Award/Grant (A) — not a market purchase or sale.
Context
- Awards and RSUs are common executive compensation and do not represent an open-market purchase or sale; they reflect pay and/or performance achievement rather than a trading signal.
- Performance-based awards mean actual vesting depends on achievement of pre-set goals for the 2023–2025 period; full ownership is subject to the vesting schedule noted above.
Insider Transaction Report
Form 4
ITRON, INC.ITRI
Reeves Donald L. III
SVP, Outcomes
Transactions
- Award
Common Stock
[F1]2026-02-18+6,527→ 25,069 total - Award
Common Stock
[F2]2026-02-18+13,490→ 38,559 total
Footnotes (2)
- [F1]One-third of this award vests on the first-year anniversary of the date of grant, and the remaining two-thirds of the?award will vest?in equal?quarterly?installments?over 24 months thereafter.
- [F2]Represents shares earned under a performance-based restricted stock unit award for the 2023-2025 performance period.
Signature
/s/ Christopher E. Ware, attorney-in-fact|2026-02-20